Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series
Kidney Diseases · 24.04.2026 · 12 (1) · 464-472
DOI: 10.1159/000552150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Diseases, online erschienen am 24.04.2026. Verfasst von Xueying Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Treatment options for IgA nephropathy (IgAN) patients with severe renal impairment are limited. Although telitacicept is approved for reducing proteinuria in IgAN, prior trials excluded patients with estimated glomerular filtration rate (eGFR) 1 g/day who received ≥24 weeks of telitacicept between March 2023 and June 2024. Proteinuria, eGFR, and serum immunoglobulins were assessed longitudinally.
Results
Thirteen patients were included. Proteinuria decreased by 45% at month 6 and remained reduced by 51%, 47%, and 45% at months 12, 18, and 24, respectively. One patient initiated dialysis at month 15. Mean eGFR remained stable over 24 months, with an annual decline slope of −2.39 mL/min/1.73 m2/year. In 8 patients, serum IgA fell from 2.93 ± 0.78 to 0.78 ± 0.28 g/L (p = 0.001) and IgG from 11.16 ± 2.92–6.53 ± 2.85 g/L (p < 0.001) at month 6, both stable through month 12. Combination therapy with glucocorticoids achieved greater proteinuria reductions at months 1–6 and a more favorable eGFR slope (+0.95 ± 6.37 vs. −3.88 ± 3.76 mL/min/1.73 m2/year) than monotherapy.
Conclusion
Telitacicept reduced proteinuria and stabilized eGFR in IgAN patients with severe renal impairment. It may be a therapeutic option for patients unresponsive or intolerant to conventional therapy, but confirmation in larger, prospective studies is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
- Department of Nephrology, Wuxi Branch of Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Wuxi, China.
- Department of Nephrology, Luwan Branch of Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Zitieren
APA
Chen, X., Wang, Z., Wang, X., Weng, Q., Chen, X., Xie, J., & Chen, Z. (2026). Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series. Kidney Diseases, 12(1), 464-472. https://doi.org/10.1159/000552150
Vancouver
Chen X, Wang Z, Wang X, Weng Q, Chen X, Xie J, et al. Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series. Kidney Diseases. 2026;12(1):464-472. doi:10.1159/000552150
BibTeX
@article{Chen2026,
author = {Chen, Xueying and Wang, Zhaohui and Wang, Xuejie and Weng, Qinjie and Chen, Xiaonong and Xie, Jingyuan and Chen, Zijin},
title = {Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series},
journal = {Kidney Diseases},
year = {2026},
volume = {12},
number = {1},
pages = {464--472},
doi = {10.1159/000552150}
}
EUVIMED